TCRX
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E N/A, PEG N/A, Graham Number None
- P/B ratio of 0.66 suggests the stock is undervalued relative to assets
- No Graham Number available due to lack of earnings
- High P/S ratio of 8.32
Ref Growth rates and Analyst Target $6.00
- Revenue growth of 286%
- Positive EPS surprise trend
- Aggressive analyst price targets
- Dependence on clinical/regulatory success
- High cash burn rate
Ref Historical price trends
- Recent 1-week price spike of 40.2%
- 5-year return of -86.4%
- Consistent history of negative earnings
Ref Piotroski F-Score 0/9
- Strong Current Ratio (8.41) provides a short-term runway
- Piotroski F-Score 0/9
- Negative ROA and ROE
Ref Yield N/A
- No dividend payments
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for TCRX and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
TCRX
TScan Therapeutics, Inc.
Primary
|
-86.4% | -42.1% | -6.5% | -43.2% | +37.5% | +40.2% |
|
OKYO
OKYO Pharma Limited
Peer
|
-54.4% | +32.0% | +47.3% | -20.3% | -1.8% | +3.8% |
|
GOSS
Gossamer Bio, Inc.
Peer
|
-95.6% | -66.2% | -57.8% | -85.5% | -26.7% | +0.4% |
|
QTI
QT Imaging Holdings, Inc.
Peer
|
-95.3% | -95.6% | -34.0% | -78.7% | +0.9% | +0.3% |
|
SERA
Sera Prognostics, Inc.
Peer
|
-80.7% | -29.7% | -32.4% | -28.1% | +20.4% | +16.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
TCRX
TScan Therapeutics, Inc.
|
BEARISH | $85.94M | - | -71.3% | -% | $1.43 | |
|
OKYO
OKYO Pharma Limited
|
BEARISH | $86.59M | - | -% | -% | $1.65 | Compare |
|
GOSS
Gossamer Bio, Inc.
|
BEARISH | $87.21M | - | -% | -% | $0.37 | Compare |
|
QTI
QT Imaging Holdings, Inc.
|
BEARISH | $83.45M | - | -% | -111.4% | $6.93 | Compare |
|
SERA
Sera Prognostics, Inc.
|
BEARISH | $90.03M | - | -51.8% | -% | $2.3 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-23 | LYNX1 CAPITAL MANAGEMENT LP | Beneficial Owner of more than 10% of a Class of Security | Purchase | 161,801 | $145,526 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
TCRX faces significant commercial risks, including potential pricing pressure from competitors and physician reluctance to adopt its engineered T cell therapies. The company also highlights that high development and manufacturing costs for these therapies may limit its competitiveness against simpler, lower-cost alternatives.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning TCRX from our newsroom.